Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmocide
Biotech
Pulmocide pulls ph. 3 antifungal trial over mortality rate
The British biotech is now performing a thorough review of the trial data to determine the future of its opelconazole program.
Darren Incorvaia
Jan 7, 2026 10:57am
Pulmocide exits OPERA with evidence of antifungal efficacy
Apr 15, 2024 9:41am
Oncorus C-suite out the door—Chutes & Ladders
Jun 9, 2023 9:30am
Sanofi-backed Jeito snags $630M fund for 12-15 European biotechs
Sep 20, 2021 1:00am
Pulmocide eyes global phase 3 registration with fresh funds
May 26, 2021 2:47pm
EuroBiotech Report: AstraZeneca, Novartis, $30M round and more
Mar 23, 2017 9:49am
